ESMO Breast Cancer Congress

An exploratory ctDNA analysis from postMONARCH highlighted the benefit of abemaciclib plus fulvestrant across HR-positive breast cancer subgroups.

Final analysis of SGNTUC-019 showed a 41.9% ORR, an 80.6% DCR, and a 18.2-month DOR with tucatinib/trastuzumab in pretreated, HER2-mutated metastatic breast cancer.

T-DM1 plus palbociclib showed significant PFS in patients with HER2-positive metastatic breast cancer.

EL1SSAR data reinforce the importance of PD-L1 assessment to select patients with TNBC with the best outcomes on atezolizumab.

Baseline ctDNA concentration was shown to be the most significant predictor of distant recurrence-free survival in patients with early breast cancer.

Zanidatamab/chemotherapy showed early antitumor activity with a manageable safety profile in patients with HER2-expressing metastatic breast cancer.

Durvalumab plus tremelimumab and trastuzumab produced responses in trastuzumab-resistant, HER2-positive advanced breast cancer.

Frontline endocrine therapy plus entrectinib failed to decrease RCB to 0/1 in patients with invasive lobular breast carcinoma.

Iza-bren was safe and displayed early clinical activity in patients with heavily pretreated breast cancer across both HER2-low and HER2-negative subgroups.

An analysis from PADA-1 showed the emergence of ESR1 mutations was uneven over time in hormone receptor–positive, HER2-negative metastatic breast cancer.

Neoadjuvant data from the ADAPTcycle trial confirmed the limited benefit of chemotherapy over endocrine therapy in high-risk HR-positive breast cancer.

Emiltatug Ledadotin generated initial responses and was tolerable in heavily pretreated patients with advanced/metastatic TNBC.

Puxitatug samrotecan demonstrated manageable safety and early efficacy in HR-positive/HER2-negative advanced breast cancer.

Adjuvant pertuzumab with trastuzumab and chemotherapy extended OS vs placebo with trastuzumab and chemotherapy in HER2-positive early breast cancer.

Treatment with T-DXd improved outcomes vs chemotherapy in pretreated patients with HR-positive, HER2-low/-ultralow metastatic breast cancer.

Subgroup analyses from EMBER-3 continued to demonstrated benefits with imlunestrant plus abemaciclib in ER-positive advanced breast cancer.

Dose reductions of ribociclib plus an NSAI did not decrease the regimen’s efficacy in patients with HR-positive, HER2-negative early breast cancer.

PF-07220060 plus endocrine therapy was tolerable and generated robust response rates in HR-positive, HER2-negative metastatic breast cancer.

Adding denosumab to neoadjuvant nab-paclitaxel did not improve 5-year invasive disease-free survival rates in patients with early-stage breast cancer.

Capivasertib plus fulvestrant improved time to second progression in patients with pretreated HR-positive, HER2-negative advanced breast cancer.

Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.

Datopotamab deruxtecan was associated with lower rates of high-grade TRAEs vs chemotherapy in the phase 3 TROPION-Breast01 trial.

Vepdegestrant plus palbociclib maintained clinical efficacy and safety in patients with pretreated, advanced ER-positive, HER2-negative breast cancer.

Atezolizumab plus chemotherapy did not improve OS vs chemotherapy alone in select patients with early relapsing triple-negative breast cancer.

Olaparib, durvalumab, and fulvestrant produced a 66.7% 24-week PFS rate in patients with endocrine-resistant, ER-positive, HER2-negative breast cancer.

First-line atezolizumab plus sacituzumab govitecan led to responses in PD-L1–positive locally advanced or metastatic triple-negative breast cancer.

Sacituzumab govitecan-hziy displayed a manageable safety profile consistent with previous reports in patients with hormone receptor–positive, HER2-negative metastatic breast cancer, irrespective of UGT1A1 status, according to a safety analysis of the phase 3 TROPiCS-02 trial.

Abemaciclib plus endocrine therapy delivered sustained survival benefits with a tolerable safety profile when used as adjuvant treatment in Chinese patients with high-risk, hormone receptor–positive, HER2-negative early breast cancer.

Capivasertib plus fulvestrant provided a clinically meaningful improvement in progression-free survival over fulvestrant alone in patients with hormone receptor–positive advanced breast cancer, including those who previously received a CDK4/6 inhibitor, chemotherapy in the advanced setting, or had baseline liver metastases.

The combination of OP-1250 and palbociclib produced a tolerable safety profile and elicited tumor responses and disease stabilization in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.